Deal Structure Guide
Anatomy of a Pharma Licensing Term Sheet
Every clause that matters — and the ones most founders miss.
What a pharma licensing term sheet is
A licensing term sheet is a non-binding document that outlines the principal terms under which a licensee proposes to acquire rights to a licensor's intellectual property. In biopharma, it is the bridge between initial interest and a definitive license agreement — and it is where the economic and structural framework of the deal is established.
Term sheets are typically 8-15 pages and cover: the grant of rights (what is being licensed, to whom, for what purpose, in which territory), the economic terms (upfront, milestones, royalties), the development and commercialization obligations, governance and decision-making rights, intellectual property provisions, and termination and change of control mechanics.
While non-binding, the term sheet sets the negotiating frame for the definitive agreement. Terms included in the term sheet are presumptively agreed upon; terms omitted are at risk. Companies that accept a term sheet without scrutinizing every clause often discover in the definitive agreement phase that critical protections they assumed were standard were never on the table.
The clauses that define the deal
Grant of Rights defines what the licensee receives. The critical dimensions are: territory (global, US-only, ex-China, region-specific), field (all indications, specific indications, specific patient populations), and scope (development only, development and commercialization, manufacturing rights). Every right not explicitly retained by the licensor is presumptively granted. Licensors should define the grant narrowly and affirmatively retain everything else.
Exclusivity determines whether the licensor can grant overlapping rights to other parties. Most pharma licenses are exclusive within the defined territory and field. The licensor's leverage is in the carve-outs: retaining rights in specific indications for internal development, retaining academic research rights, or reserving the right to develop in territories not covered by the license.
Sublicensing provisions govern whether the licensee can transfer its rights to third parties. Unrestricted sublicensing rights are a significant concession — they allow the licensee to profit from re-licensing without the licensor's input on the sublicensee's identity, capabilities, or terms. Best practice: require prior written consent for sublicensing and negotiate a sublicensing revenue share (typically 25-40% of sublicense income).
Diligence obligations define what the licensee must do — and by when — to develop and commercialize the asset. Without enforceable diligence obligations, a licensee can shelve the asset indefinitely, blocking the licensor from pursuing alternative paths. The strongest diligence provisions include: minimum annual development spend, defined milestones with target dates, and use-it-or-lose-it reversion rights if milestones are missed.
What standard terms look like
Across the licensing transactions in our database, several structural patterns emerge as market standard — and deviations from these norms signal opportunity or risk.
Territory splits: approximately 45% of licensing deals grant global rights. 30% are structured as US/ex-US splits. 15% carve out China or greater China. 10% are single-territory or region-specific. The trend is toward greater territorial complexity, particularly as China-to-West deals have introduced multi-territory structuring as a standard consideration.
Diligence standards: approximately 70% of deals include some form of development diligence obligation. However, only 40% include specific timeline commitments with reversion consequences. The remainder use "commercially reasonable efforts" language — a standard that is notoriously difficult to enforce and almost always favors the licensee.
Sublicensing: approximately 60% of deals permit sublicensing with prior consent. 25% allow sublicensing without consent to affiliates but require consent for third parties. 15% allow unrestricted sublicensing — a concession that should be avoided.
Change of control: approximately 55% of deals include change-of-control provisions that give the licensor some form of protective rights (consent, termination option, or accelerated payments) if the licensee undergoes a change of control. The absence of this provision can leave the licensor's asset in the hands of a company they did not choose to partner with.
Review comparable deal structures on Solidus at calculator.ambrosiaventures.co.
What most companies get wrong
The first mistake is treating the term sheet as a formality. Founders and early-stage management teams often view the term sheet phase as a checkpoint on the way to the "real" negotiation in the definitive agreement. In practice, the term sheet sets the ceiling for what the licensor can achieve. It is far easier to negotiate protective terms into a term sheet than to introduce them in the definitive agreement phase, where the counterparty's legal team will resist any term not already contemplated.
The second mistake is failing to negotiate reversion rights. If the licensee does not develop the asset — whether due to portfolio reprioritization, a change of management, or a strategic pivot — the licensor needs a clear path to recover its rights. Reversion provisions should be specific: tied to defined milestones, with specified timelines, and without conditions that give the licensee indefinite extensions.
The third mistake is accepting "commercially reasonable efforts" as the diligence standard without definition. CRE is the most commonly litigated provision in pharma licensing. It typically means what the licensee would do for a similar compound in its portfolio — a standard that may be far below what the licensor expects. Licensors should push for defined minimum commitments alongside the CRE standard.
The fourth mistake is ignoring the accounting treatment of milestones. Under ASC 606, the timing and structure of milestone payments affect how and when the licensor recognizes revenue. Companies that accept milestone structures without consulting their auditors may find that accounting treatment creates unexpected quarter-to-quarter volatility.
Related Insights
Further reading from our research.
Bring us your transaction.
We’ll meet you at peer level — anywhere in the world.